Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective study.
Dourthe ME, Phulpin A, Auperin A, Bosq J, Couec ML, Dartigues P, Ducassou S, Garnier N, Haouy S, Leblanc T, Leruste A, Paillard C, Rigaud C, Simonin M, Patte C, Minard-Colin V. Dourthe ME, et al. Haematologica. 2022 Sep 1;107(9):2173-2182. doi: 10.3324/haematol.2021.280257. Haematologica. 2022. PMID: 35236054 Free PMC article.
Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia.
Alcantara M, Simonin M, Lhermitte L, Touzart A, Dourthe ME, Latiri M, Grardel N, Cayuela JM, Chalandon Y, Graux C, Dombret H, Ifrah N, Petit A, Macintyre E, Baruchel A, Boissel N, Asnafi V. Alcantara M, et al. Among authors: dourthe me. Blood Adv. 2019 Jul 9;3(13):1981-1988. doi: 10.1182/bloodadvances.2018028993. Blood Adv. 2019. PMID: 31270080 Free PMC article.
IKZF1 alterations predict poor prognosis in adult and pediatric T-ALL.
Simonin M, Lhermitte L, Dourthe ME, Lengliné E, Graux C, Grardel N, Cayuela JM, Arnoux I, Gandemer V, Ifrah N, Dombret H, Baruchel A, Macintyre E, Petit A, Boissel N, Asnafi V. Simonin M, et al. Among authors: dourthe me. Blood. 2021 Mar 25;137(12):1690-1694. doi: 10.1182/blood.2020007959. Blood. 2021. PMID: 33150353 Free article. No abstract available.
Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL.
Simonin M, Schmidt A, Bontoux C, Dourthe MÉ, Lengliné E, Andrieu GP, Lhermitte L, Graux C, Grardel N, Cayuela JM, Huguet F, Arnoux I, Ducassou S, Macintyre E, Gandemer V, Dombret H, Petit A, Ifrah N, Baruchel A, Boissel N, Asnafi V. Simonin M, et al. Among authors: dourthe me. J Hematol Oncol. 2021 May 3;14(1):74. doi: 10.1186/s13045-021-01068-4. J Hematol Oncol. 2021. PMID: 33941203 Free PMC article.
PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALL.
Andrieu GP, Kohn M, Simonin M, Smith CL, Cieslak A, Dourthe MÉ, Charbonnier G, Graux C, Huguet F, Lhéritier V, Dombret H, Spicuglia S, Rousselot P, Boissel N, Asnafi V. Andrieu GP, et al. Among authors: dourthe me. Blood. 2021 Nov 11;138(19):1855-1869. doi: 10.1182/blood.2020010081. Blood. 2021. PMID: 34125178 Free PMC article. Clinical Trial.
Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins.
Steimlé T, Dourthe ME, Alcantara M, Touzart A, Simonin M, Mondesir J, Lhermitte L, Bond J, Graux C, Grardel N, Cayuela JM, Arnoux I, Gandemer V, Balsat M, Vey N, Macintyre E, Ifrah N, Dombret H, Petit A, Baruchel A, Ruminy P, Boissel N, Asnafi V. Steimlé T, et al. Among authors: dourthe me. Blood Cancer J. 2022 Jan 26;12(1):14. doi: 10.1038/s41408-022-00613-9. Blood Cancer J. 2022. PMID: 35082269 Free PMC article.
Harnessing the MYB-dependent TAL1 5'super-enhancer for targeted therapy in T-ALL.
Smith C, Touzart A, Simonin M, Tran-Quang C, Hypolite G, Latiri M, Andrieu GP, Balducci E, Dourthe MÉ, Goyal A, Huguet F, Petit A, Ifrah N, Baruchel A, Dombret H, Macintyre E, Plass C, Ghysdael J, Boissel N, Asnafi V. Smith C, et al. Among authors: dourthe me. Mol Cancer. 2023 Jan 18;22(1):12. doi: 10.1186/s12943-022-01701-x. Mol Cancer. 2023. PMID: 36650499 Free PMC article.
36 results